Faricimab for nAMD and DME: Welcome to the real world
Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)
The case for ultrawidefield-guided swept-source OCT
The technology provides effective, efficient evaluations when paired with the right patients
New MIGS devices aid patients and test patience
In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices
Cannabis use carries no risk of primary open-angle glaucoma
Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma
Cross-linking in paediatric patients: The case for treating keratoconus without waiting for disease progression
The case for treating keratoconus without waiting for disease progression
Next-gen lasers and IOLs for every patient: the year ahead in cornea
Why “acceleration” is the industry keyword for 2024
In 2024, data-driven tools will shape cataract and refractive surgery
Working smarter, not harder, to benefit patients
Virtual simulations improve global surgical outcomes
Orbis advances cataract surgery training in low-resource areas with technology
AAO 2023 brings data, diagnostics and digital workflows to the forefront
Experts from around the globe converged in San Francisco, California
Why the future of ophthalmology is in corneal grafts
Restoration and regeneration represent a new paradigm
A global view of diabetic eye disease
At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research
Cellular evidence of retinal ganglion cell transfection after LHON treatment
Data show transfection in both eyes despite unilateral injection
